# HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions

> **NCT03184597** · NA · UNKNOWN · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 4000 (estimated)

## Conditions studied

- Epilepsy
- Neuropathy
- Psychiatric Illness
- Blepharospasm

## Interventions

- **DIAGNOSTIC_TEST:** HLA screening before commencing aromatic AEDs

## Key facts

- **NCT ID:** NCT03184597
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-01
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2018-09-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184597, "HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03184597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*